Canaccord analyst William Plovanic lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $7 from $12 and keeps a Buy rating on the shares. The firm reported A4 results inline with its preanouncement and its guidance reiterated with 2026 expected to be back end loaded due to the doubling of its sales force.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M
- TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c)
- TLSI Earnings this Week: How Will it Perform?
- TriSalus Life Sciences Prices Underwritten Public Equity Offering
- TriSalus Life Sciences 9.76M share Spot Secondary priced at $4.10